AI assistant
ADALTA LIMITED — AGM Information 2018
Apr 17, 2018
64247_rns_2018-04-17_ddb9872e-ec30-4214-ba39-196f3b032f84.pdf
AGM Information
Open in viewerOpens in your device viewer
ASX Announcement
AdAlta shareholder information sessions
MELBOURNE Australia, 18[th] April, 201 8 : AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to invite shareholders to attend information briefing sessions to discuss the significant improvement to its lead therapeutic program AD-214.
Shareholder briefing sessions:
The following sessions are available to those shareholders able to attend:
| Melbourne: | Monday, 23rdApril, 10:00amCSBC: Level 14, 330 Collins Street, Melbourne | |
|---|---|---|
| Brisbane: | Tuesday 24thApril, 10:00amBentleys Queensland: Level 9, 123 Albert Street Brisbane QLD 4000 | |
| Perth: | Thursday 26thApril, 11:00 amPatersons Stockbroking: Level 23, Exchange Tower, 2 The Esplanade, Perth | |
| Sydney: | Monday, 30th April, 10:00 amFB Rice: Level 23, 44 Market Street, Sydney |
Please RSVP to attend
Shareholders wishing to register interest in attending one of the events outlined below should RSVP by phoning Ebony Fietz on +61 0409 018 525 or by using the Contact Us form on the AdAlta website at http://adalta.com.au/contact-us/ or emailing [email protected]. At the time of RSVP, please note your: name, email, contact number and which briefing session is of interest (Sydney, Melbourne, Brisbane or Perth.)
The AdAlta team looks forward to seeing those shareholders who are able to attend.
Notes to Editors
About AdAlta
AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.
I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.
We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i- bodies, for use in treating serious diseases.
AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.
The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.
Further information can be found at: www.adalta.com.au.
For more information, please contact:
AdAlta Limited Sam Cobb, CEO Tel: +61 (0)3 9479 5159 E: [email protected]